354 related articles for article (PubMed ID: 10026839)
21. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
22. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
Nakamura S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Yamamura Y; Mori T; Tominaga M
J Pharmacol Exp Ther; 2000 Dec; 295(3):1005-11. PubMed ID: 11082435
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):63-9. PubMed ID: 9459574
[TBL] [Abstract][Full Text] [Related]
24. Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney.
Barthelmebs M; Krieger JP; Grima M; Nisato D; Imbs JL
Eur J Pharmacol; 1996 Oct; 314(3):325-32. PubMed ID: 8957254
[TBL] [Abstract][Full Text] [Related]
25. The modulatory effect of nitric oxide in pro- and anti-convulsive effects of vasopressin in PTZ-induced seizures threshold in mice.
Javadian N; Rahimi N; Javadi-Paydar M; Doustimotlagh AH; Dehpour AR
Epilepsy Res; 2016 Oct; 126():134-40. PubMed ID: 27497813
[TBL] [Abstract][Full Text] [Related]
26. Characterization of receptors mediating contraction of the rat isolated small mesenteric artery and aorta to arginine vasopressin and oxytocin.
Stam WB; Van der Graaf PH; Saxena PR
Br J Pharmacol; 1998 Oct; 125(4):865-73. PubMed ID: 9831926
[TBL] [Abstract][Full Text] [Related]
27. Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats.
Loichot C; Cazaubon C; De Jong W; Helwig JJ; Nisato D; Imbs JL; Barthelmebs M
Naunyn Schmiedebergs Arch Pharmacol; 2000 Mar; 361(3):319-26. PubMed ID: 10731046
[TBL] [Abstract][Full Text] [Related]
28. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
Akerlund M; Bossmar T; Brouard R; Kostrzewska A; Laudanski T; Lemancewicz A; Serradeil-Le Gal C; Steinwall M
Br J Obstet Gynaecol; 1999 Oct; 106(10):1047-53. PubMed ID: 10519430
[TBL] [Abstract][Full Text] [Related]
29. Binding of [3H] SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranes.
Serradeil-Le Gal C; Raufaste D; Marty E; Garcia C; Maffrand JP; Le Fur G
Biochem Biophys Res Commun; 1994 Feb; 199(1):353-60. PubMed ID: 8123034
[TBL] [Abstract][Full Text] [Related]
30. A nonpeptide vasopressin V(1a) receptor antagonist, SR 49059, does not prevent cisplatin-induced emesis in piglets.
Grélot L; Girod V; Dapzol J; Maffrand JP; Serradeil-Le Gal C
Fundam Clin Pharmacol; 2001 Jun; 15(3):189-200. PubMed ID: 11468030
[TBL] [Abstract][Full Text] [Related]
31. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
[TBL] [Abstract][Full Text] [Related]
32. Acute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V
Taveau C; Chollet C; Bichet DG; Velho G; Guillon G; Corbani M; Roussel R; Bankir L; Melander O; Bouby N
Am J Physiol Endocrinol Metab; 2017 Mar; 312(3):E127-E135. PubMed ID: 27998960
[TBL] [Abstract][Full Text] [Related]
33. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
[TBL] [Abstract][Full Text] [Related]
34. Body temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin and the non-peptide oxytocin receptor agonist WAY 267,464: a biotelemetry study in rats.
Hicks C; Ramos L; Reekie T; Misagh GH; Narlawar R; Kassiou M; McGregor IS
Br J Pharmacol; 2014 Jun; 171(11):2868-87. PubMed ID: 24641248
[TBL] [Abstract][Full Text] [Related]
35. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
[TBL] [Abstract][Full Text] [Related]
36. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
Pieniaszek HJ; Sy SK; Ebling W; Fossler MJ; Cain VA; Mondick JT; Ma S; Kornhauser DM
J Clin Pharmacol; 2002 Jul; 42(7):738-53. PubMed ID: 12092741
[TBL] [Abstract][Full Text] [Related]
37. Selective blockade of vasopressin V2 receptors reveals significant V2-mediated water reabsorption in Brattleboro rats with diabetes insipidus.
Pouzet B; Serradeil-Le Gal C; Bouby N; Maffrand JP; Le Fur G; Bankir L
Nephrol Dial Transplant; 2001 Apr; 16(4):725-34. PubMed ID: 11274265
[TBL] [Abstract][Full Text] [Related]
38. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists.
Perucca J; Bichet DG; Bardoux P; Bouby N; Bankir L
J Am Soc Nephrol; 2008 Sep; 19(9):1721-31. PubMed ID: 18596120
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats.
Tomura Y; Tahara A; Tsukada J; Yatsu T; Uchida W; Iizumi Y; Honda K
Clin Exp Pharmacol Physiol; 1999; 26(5-6):399-403. PubMed ID: 10386228
[TBL] [Abstract][Full Text] [Related]
40. Effect of small molecule vasopressin V1a and V2 receptor antagonists on brain edema formation and secondary brain damage following traumatic brain injury in mice.
Krieg SM; Sonanini S; Plesnila N; Trabold R
J Neurotrauma; 2015 Feb; 32(4):221-7. PubMed ID: 25111427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
